{"ticker": {"uuid": "8c2744a1-ae90-415d-86bf-993508c43fec", "symbol": "DCTH", "name": "Delcath Systems Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Understanding Momentum Shifts in (DCTH)", "summary": "Delcath Systems Inc. (NASDAQ: DCTH) is showing neutral near-term sentiment with strong mid-term sentiment potentially stalling. The analysis identifies no clear price positioning signal but notes compelling upside potential as no resistance levels remain above the current price. ", "url": "https://news.stocktradersdaily.com/news_release/132/Understanding_Momentum_Shifts_in_DCTH_071126104402_1783824242.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T22:44:00", "published_display": "11 Jul 2026 22:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems (DCTH) Slides 3.77% as Stock Tests Key Support Levels - Flat Correction", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOenpxcFR0VXRGS3pVVkxEVmNJUUJxVGZyZnhIb3NWVEFqeTh6RzRwektrWC1BdXdZQVc5N2RXRmRxVDZEYjBucm4yVWRSUVpOLUV1RmVlSXZwQmVjbHVOM1Q0aGgwakpwMUF3NHB6ZWpUcFFvTjQzcnhoQkJPMmdYYzlLOWVCdGNHcjRmSHV4TnpkT0ZHR2hDTEFLY2dVZG5zRmhOeDliR2hxLXJs?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T15:42:03+00:00", "published_display": "11 Jul 2026 15:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervalued", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQNG9xRUQ0elZLbXVRNmVRU3hhQjNSSFRCYWtMTUZ1OEJDWkF3RjQzNFNCVHJlN2RGY3RJLV84dWZNZUhZaDRwWVl2SFhIdWM5OC1oZ2JmcnczS090WXNwendUQWlWYXB5UjA1RF9RdW0telowS1NKdEd2STFRbDNPdEZxbEFPSmowMWZfX1lBN3lfblBpNElZRVpEeVpLSzJBR29FVzdMNXI4Ulh4eC0wZU1tdk5jd204MXpFZm5iaE5zdFcyRy1v?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-10T23:56:15+00:00", "published_display": "10 Jul 2026 23:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Maintains Delcath Systems(DCTH.US) With Buy Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQcGczMVJGUVJad1Rkd2JNLVFmdWtSdmRKZXhWSWVJVzg0LXRFblZISl8yYWV2MFpoYllDeDBDUE9uRElQZEhUbGxPNElMVklMZG9nRERTRFFhbEwwSkllTm9pcmlfdzQtaEZLVS1QRlN6eXMwbGFWbzRLXzg1VW9IYmdVd0JjWmg0S3hoRXN3UU9od3hOczd5XzZJOTJvS1JmUTg2Tg?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-10T11:34:11+00:00", "published_display": "10 Jul 2026 11:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $21", "summary": "CCORF has reiterated its Buy rating for Delcath Systems (DCTH.US), maintaining a target price of $21. This indicates continued confidence from the firm in the company's prospects.", "url": "https://www.moomoo.com/news/post/72780649/ccorf-maintains-delcath-systems-dcthus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-10T12:09:42", "published_display": "10 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Doses First Patient in Mid-Stage Trial of Hepzato", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/delcath-systems-doses-first-patient-124419614.html", "source_name": "MT Newswires", "published_at": "2026-07-09T12:44:19+00:00", "published_display": "09 Jul 2026 12:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath starts Phase 2 HEPZATO trial in metastatic breast cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNTmRLczFUVmJEY09XbkZhSkx3WGY4dzQxYUMzUFprU3JVMFI3eWQ1LVExQTBwYllaX1pQcFJJVG91ZmdveDhEZ0lmeHFwNDg2T1d2R3hwZURqSm1Mcjh1M2dMYkpGUDE4cUlkdHphNk1aR0ZFUzNpa0tqNlk4TmV5VHN6TG9GbHVHa1YwS1FGTUlTdWgxVGtiVWo5NHp0ZmpEdjJSN2htR2Q4SWk4SFd1NUpLVEd6aENGQklyXw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T12:00:00+00:00", "published_display": "09 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems begins Phase 2 breast cancer trial", "summary": "Delcath Systems has dosed the first patient in a Phase 2 trial for its HEPZATO treatment, targeting liver-dominant HER2-negative metastatic breast cancer patients who have failed prior treatments. The trial aims to enroll approximately 90 patients across more than 20 global sites", "url": "https://grafa.com/en/news/united-states/delcath-systems-doses-first-breast-cancer-patient", "source_name": "grafa.com", "published_at": "2026-07-09T12:25:00", "published_display": "09 Jul 2026 12:25", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO\u2122 in Liver-Dominant Metastatic Breast Cancer", "summary": "Delcath Systems announced that the first patient has been dosed in its global Phase 2 clinical trial (DELUMA) evaluating HEPZATO in combination with standard of care for liver-dominant metastatic breast cancer. This randomized, controlled trial will enroll approximately 90 patien", "url": "https://uk.finance.yahoo.com/news/delcath-systems-announces-first-patient-120000662.html", "source_name": "Market source", "published_at": "2026-07-09T12:13:17", "published_display": "09 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath doses first patient in breast cancer trial in Milan", "summary": "Delcath Systems Inc. has dosed the first patient in its Phase 2 clinical trial (DELUMA) in Milan, Italy, evaluating HEPZATO combined with standard of care for liver-dominant metastatic breast cancer. This trial aims to assess the safety and efficacy of HEPZATO in HER2-negative pa", "url": "https://www.investing.com/news/company-news/delcath-doses-first-patient-in-breast-cancer-trial-in-milan-93CH-4783969", "source_name": "Investing.com", "published_at": "2026-07-09T12:13:17", "published_display": "09 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems (DCTH) Gains 2.12% as Stock Approaches Key Resistance Level - GEX Level", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNNkxadUhlNFl0eUdQZDd0TnhjRkZhSm9Dc3hrSlhvaHJjdUZRdTZyQzZsX1FFNjY0N3FJVDRZOHczd01LV1VudTZfRWZUbXZKY0p0NDZ1TnhYZ3l6Y25PcmxMVTZYdVBDWG5qelZYSFNpV0Jxb2JNaHFERF9LT0dqbEVtN0JrZ09uVjV4bXNZbV9RSElWdEdZOHJMSHZaSHNwYy1ZRHB5Zm45SGtkaUZ1ZGN3clF4YzFEN2c?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-07T00:46:34+00:00", "published_display": "07 Jul 2026 00:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Delcath Systems, Inc. \u2013 NASDAQ:DCTH", "summary": "This article provides the \"Price to sales forward\" metric for Delcath Systems, Inc. (NASDAQ: DCTH) on TradingView. It appears to be a financial data snippet rather than an in-depth analysis, focusing solely on this specific financial ratio for the company. The page also includes ", "url": "https://www.tradingview.com/symbols/NASDAQ-DCTH/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T23:10:23", "published_display": "01 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (DCTH) Movement", "summary": "This article provides a real-time signal analysis for Delcath Systems Inc. (DCTH), highlighting strong near and mid-term sentiment and compelling upside potential due to an absence of resistance above the current price. It outlines institutional trading strategies including posit", "url": "https://news.stocktradersdaily.com/news_release/139/Avoiding_Lag:_Real-Time_Signals_in_DCTH_Movement_063026093602_1782869762.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T21:40:52", "published_display": "30 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc.(NasdaqCM:DCTH) added to Russell Small Cap Comp Value Benchmark", "summary": "Delcath Systems, Inc. (NasdaqCM:DCTH) has been added to the Russell Small Cap Comp Value Benchmark. This inclusion is a significant development for the interventional oncology company, whose proprietary products focus on treating primary and metastatic liver cancers. The announce", "url": "https://www.marketscreener.com/news/delcath-systems-inc-nasdaqcm-dcth-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfde8df225", "source_name": "marketscreener.com", "published_at": "2026-06-29T11:10:24", "published_display": "29 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Delcath Systems, Inc. \u2013 SWB:DV3R", "summary": "This article displays the \"Price to book forward\" financial metric for Delcath Systems, Inc. (SWB:DV3R) on the Stuttgart Stock Exchange. It indicates that the market was closed with no trades at the time of the report. The content provides a basic financial overview for this spec", "url": "https://www.tradingview.com/symbols/SWB-DV3R/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T07:09:44", "published_display": "29 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Delcath Systems, Inc. \u2013 NASDAQ:DCTH", "summary": "This article provides financial information for Delcath Systems, Inc. (NASDAQ: DCTH), specifically focusing on its forward price-to-earnings ratio. It displays a \"Period,\" \"Value,\" \"Change,\" and \"Change %\" table, indicating that the data was made by humans. The content is essenti", "url": "https://www.tradingview.com/symbols/NASDAQ-DCTH/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:09:44", "published_display": "29 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc.(NasdaqCM: DCTH) added to Russell 3000 Value Benchmark", "summary": "Delcath Systems, Inc. (NasdaqCM: DCTH), an interventional oncology company specializing in liver cancer treatments, has been added to the Russell 3000 Value Benchmark. This inclusion follows several other recent additions to various Russell indices, including the Russell Microcap", "url": "https://www.marketscreener.com/news/delcath-systems-inc-nasdaqcm-dcth-added-to-russell-3000-value-benchmark-ce7f5fdcd18ef026", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T11:10:24", "published_display": "28 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc.(NasdaqCM: DCTH) added to Russell 2000 Defensive Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPVTZFOTVoYUdRaTlzWnFMd253eDRkYTIxZHVwc1ZsazB4UjIzQTVfLVFVQzREYkRpbk1kNW53SU96RUtjS0FxTEFaaUtPZXNNMVBCZ3N5aEdMWUk2Yk43RDVsTndlWFRVR0huYk04LVRqSzdTc3h4Mmx3cmFuZC1jU3RSV1FEZnJIbGRNeDN5OE5MXzJmRU9ZZWhnUnczaWRfUW1abkczTEhwajVIa0tXZmtFQm85VFVVeldjUDFmNnNQQQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc. Actuals & Estimates (FWB:DV3R)", "summary": "This article provides financial actuals and estimates for Delcath Systems, Inc. (FWB:DV3R), offering insights into its income statement, balance sheet, cash flow, and valuation metrics. It includes analyst forecasts, historical price data, upcoming earnings dates, and details on ", "url": "https://www.tradingview.com/symbols/FWB-DV3R/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T19:40:59", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc. Actuals & Estimates (NASDAQ:DCTH)", "summary": "This article provides an overview of Delcath Systems, Inc. (NASDAQ:DCTH), including its current stock price, historical performance, and analyst forecasts. It details financial actuals and estimates, earnings per share, revenue, net income, and its market capitalization, and also", "url": "https://www.tradingview.com/symbols/NASDAQ-DCTH/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:59", "published_display": "26 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DCTH Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Delcath Systems, Inc. (DCTH) currently trades at $12.32, with analysts providing a 1-year price target ranging from $16.00 to $30.00. The company's stock has seen a 1.90% increase over the past week and a 10.99% rise over the last month, despite a -11.37% decrease over the last y", "url": "https://www.tradingview.com/symbols/NASDAQ-DCTH/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T08:12:24", "published_display": "26 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc. Actuals & Estimates (LS:A2PT5P)", "summary": "This article provides an overview of Delcath Systems, Inc. (A2PT5P) stock, including current price, analyst forecasts, market capitalization, and financial performance. It highlights key financial metrics, past earnings, and upcoming earnings dates, along with offering guidance o", "url": "https://www.tradingview.com/symbols/LS-A2PT5P/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:40:32", "published_display": "26 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotting Winners: Merit Medical Systems (NASDAQ:MMSI) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q1", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPZ3VmWDdGZC04R2RXUUJZTHJqVlJrdnhJYy1LaEJkcHBaWi1sWXdoWS1oLWFlVUQxdFNOQlNDdzhaTHJtMGRkX3pHc1pWbGp0bENwY1h6TlpvWVRWWmJxODh4emhGVDBFajd0VWNmUGNVcnN1SDBXRG9jZFVDa2M4MGFCVFhxbGN0ZXZqSTV2SUE1S3JjMTRnQlBiSnVmR0lv?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Institutional Confidence", "summary": "Delcath Systems Inc (DCTH) has an institutional shareholding score of 3.00, placing it 132nd out of 203 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion decreased by 20.44% quarter-over-quarter to 49.40%, with Bill Nygren | OAKMX being th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T18:39:23", "published_display": "18 Jun 2026 18:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Delcath Systems Inc (DCTH), focusing on its business segments. As of the latest update on April 6, the company's revenue is primarily driven by HEPZATO KIT, accounting for 92.50% of revenue with $78.83 million, while CHEMOSAT contribu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T18:09:53", "published_display": "18 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Delcath Systems Inc (DCTH) currently has a strong financial score of 8.31, placing", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:33", "published_display": "18 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Delcath Systems Inc (DCTH), detailing its current price momentum score, support and resistance levels, and various technical indicator and moving average signals. Currently, the stock's price momentum score is 9.38, suggesting a range", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/technical", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:33", "published_display": "18 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Valuation: PE, PB & Fair Value Analysis", "summary": "Delcath Systems Inc (DCTH) has a current valuation score of 4.97, placing it low within the Healthcare Equipment & Supplies industry. Its P/E ratio stands at 805.54, which is at its recent high and significantly above its recent low. However, relevant data for P/B, P/S, and P/CF ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:33", "published_display": "18 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a detailed look into Delcath Systems Inc (DCTH)'s dividend and stock split history. It states that the company has distributed no dividends in the past five years and has no record of stock splits. The page also displays current market data for DCTH, includin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:33", "published_display": "18 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Delcath Systems Inc (DCTH) has an earnings forecast score of 8.57, ranking 26th in the Healthcare Equipment & Supplies industry, with an average price target of $22.00. Based on 6 analysts, the stock has a \"Buy\" rating with a target price of $22.333, representing an upside of 89.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:29", "published_display": "17 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 2026 Delcath Systems Inc Earnings Call Transcript", "summary": "This document contains the transcript for Delcath Systems Inc.'s Q1 2026 earnings conference call, which took place on May 7, 2026, at 12:30 PM GMT. The call commenced with an introduction and then transitioned to discussions of the company's first-quarter 2026 earnings. The prov", "url": "https://www.gurufocus.com/stock/STU:DV3R/transcripts/8844756", "source_name": "GuruFocus", "published_at": "2026-06-16T07:40:04", "published_display": "16 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc. Analyst Forecast (DCTH) \u2014 MLQ", "summary": "This article provides an analyst forecast for Delcath Systems, Inc. (DCTH), showing a \"Buy\" consensus from 11 analysts with a 12-month average target price of $23.00. It details forward estimates for revenue, EPS, and net income through 2030, alongside recent grade changes and pr", "url": "https://mlq.ai/stocks/v2/DCTH/stock-forecast/", "source_name": "MLQ.ai", "published_at": "2026-06-08T11:09:53", "published_display": "08 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc. Stock 12\u2011Month Price Target Cut to $20.83, Implies 95% Upside", "summary": "Delcath Systems, Inc.'s average 12-month price target has been lowered to $20.83 from $21.71 by 6 analysts, with individual forecasts ranging from $16 to $30. This new target suggests a potential upside of approximately 95% based on the June 5 closing price. The consensus analyst", "url": "https://www.tradingview.com/news/tradingview:48f8ca0a8615d:0-delcath-systems-inc-stock-12-month-price-target-cut-to-20-83-implies-95-upside/", "source_name": "TradingView", "published_at": "2026-06-06T16:38:54", "published_display": "06 Jun 2026 16:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European cancer guidelines add Delcath liver therapy for eye melanoma", "summary": "Delcath Systems' CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (M-PHP) has been included in the European Society for Medical Oncology (ESMO)\u2013EURACAN Clinical Practice Guidelines for uveal melanoma. This inclusion validates M-PHP as a recommended li", "url": "https://www.stocktitan.net/news/DCTH/delcath-systems-inc-announces-inclusion-of-chemosat-hepatic-delivery-kmiustvc4nvx.html", "source_name": "Stock Titan", "published_at": "2026-06-06T00:38:54", "published_display": "06 Jun 2026 00:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC", "summary": "The article announces that DELCATH SYSTEMS INC (DCTH) has received FDA approval for its product, HEPZATO. This information was disseminated by Quantisnow, a platform providing real-time market data and news to investors. Quantisnow Plus members were alerted of this development sh", "url": "https://www.quantisnow.com/insight/fda-approval-for-hepzato-issued-to-delcath-systems-inc-6578811", "source_name": "Quantisnow", "published_at": "2026-05-29T11:09:13", "published_display": "29 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(DCTH) Movement Within Algorithmic Entry Frameworks", "summary": "Delcath Systems Inc. (NASDAQ: DCTH) is exhibiting weak near-term sentiment that may lead to a resumption of long-term weakness. The article highlights an exceptional 57.7:1 risk-reward short setup and outlines three distinct AI-generated trading strategies with specific entry zon", "url": "https://news.stocktradersdaily.com/news_release/1/DCTH_Movement_Within_Algorithmic_Entry_Frameworks_052826054602_1780004762.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-28T17:46:00", "published_display": "28 May 2026 17:46", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts", "summary": "Delcath Systems, Inc. announced the publication of two investigator-initiated trials-in-progress abstracts for the 2026 ASCO Annual Meeting. These abstracts detail ongoing clinical investigations using Delcath's HEPZATO KIT\u2122 for metastatic melanoma involving the liver. The trials", "url": "https://finance.yahoo.com/sectors/healthcare/articles/delcath-systems-announces-two-asco-200100337.html", "source_name": "Market source", "published_at": "2026-05-27T09:10:06", "published_display": "27 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liver melanoma trials test HEPZATO with systemic treatments at ASCO 2026", "summary": "Delcath Systems announced the publication of two investigator-initiated trials-in-progress abstracts for presentation at the 2026 ASCO Annual Meeting. These abstracts detail ongoing clinical investigations evaluating HEPZATO KIT\u2122 Hepatic Delivery System (HDS) with melphalan in co", "url": "https://www.stocktitan.net/news/DCTH/delcath-systems-announces-two-asco-2026-investigator-initiated-dp5wpwdiapnc.html", "source_name": "Stock Titan", "published_at": "2026-05-27T08:10:45", "published_display": "27 May 2026 08:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Delcath Systems (DCTH) director awarded 22,500 stock options at $11.61", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNWEREWW9nR21FeWppZzFVSmFEbC1UTTRxa2xKRGZQNXNkeGl4d0J0ajdaMDk4elpmMlpRblFLb0VsN28tZTdzRW9uQ1FTSVBwcTRpb1BhRDZ1TllqQ2Q4aTA5V2g1cW1DdkZWNktoMTl1eDhXWjhFT2dySm5hdTZXTTRFeUI2REx3MHk3dUhBaks5Y0dEaGwyZURoc0thcEpoalZiaGI1NVoweWR0SE10dWQ4dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath (DCTH) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/38459c2a-38ca-31ab-a108-c9d47b74b4b4/delcath-%28dcth%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-08T16:25:55+00:00", "published_display": "08 May 2026 16:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems (DCTH) Trailing Profitability Flip Tests Bullish Margin Expansion Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/7bf08e38-3fd6-340b-89e9-a4a599ba6e25/delcath-systems-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-07T17:42:42+00:00", "published_display": "07 May 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZ0trOWhRTUdSQXN4emRSWU9ucE5zNV9Fc2wwQnBzLTVtOGp5R2NsS0lfV3RkRURBdEpiRW9hVmhsaTNlMGFNcWVRaHhSM18xVTlsRmJVUVJrVExvS3pNM2diODVRRzBJZS04MDhYb0ttVGtkdVdEbkJ0Sjd5TW1PQkY3b1I4b05zNmJBUWJSUzFCSXozTGNNU2cycjU3UQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The Delcath Systems (DCTH) Story Is Shifting With Hepzato Milestones And 2026 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNdFhHM2gzQ3FhUjhJNjF4c0xKWWZJS0dCNlJ1UGFjamFIZXQ3Z1l6VmZ2VWM4bUd4djViYlJ3MGI4NnFYOUZUOTQ1TnJUYU0zZHNFMHdVRGxpWThFMFNlLWpVMENnWXQ4MjM3MHVmeEZZOE5uOXN4bkotU3NDOERIVnhLVmdQYUFUQlRaeGZYVVhjcS1jeFZNbXE1OVpOSFd6VFE?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Delcath Systems will discuss Q1 results on a May 7 morning call", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOX1JOdmdKb3FWLU4xRGpLRFJrbmdfM0NiMUFjTERpLWplU3F5QzViM0tJRlNJWXJFd2dXRkdSOXpGUUllek5QNGdyU3lvYmRRNjNlckdLbFB2cFRVT0xDQzh2MWY0TmNyNkRfTUs2b1E2V2JTOVFsNVM4N0xsOWtiY1ZycmFwZ2NBWXBEaGlEM1dteEFRNVVvOWQ5X0xCUGs1QWQ5dG1HOUF4Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T12:42:40+00:00", "published_display": "23 Apr 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q4 Highlights: Merit Medical Systems (NASDAQ:MMSI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQdTQyU1EtSEFYQTdZR0NhU1ZpMVdGNXhiTnlkNm9RWFRka3RfYlZBeklfTFZTRkVaOHBGNi15enNqMGlxVnJad0M5cmp3dUZzYW9Va2tOU19sMnE4V1czcFB4VWRKaVBzYnRtZ0RfVnB5TkloY3U5dW4wQllJMDJaS3BQSVNOMHlVRFQ4aDYtSV9HNTViZXc?oc=5", "source_name": "Market source", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath: Fundamentals Intact, Despite Share Price Weakness (NASDAQ:DCTH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPYWJGWXlzVUNlT1FHSDFZX3Z3OFQ1OHdtOTR0VzBOYXhVS19rVXF1bXk3QjhFazVtMDlJUE1UOS14TGt1SjJNVzhjZHlVZms1aG5SXzZYSTltYXJveVQxNmhqYkZtRjFkVlZPdXNBZjVDNklLS1JpRkFBZXdkbnlEdm16SXB1QkNqT1R4b3JKSmhRRUxJQ0dERjh6LUlRdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade (NASDAQ:DCTH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQZFRsQ2gyeERKNWVTU2M1WW53bDFGTnEwQmwyQmtrMDloWjJhV3UyT19yY1BXQXJhd0JPYXg2TThCRTJqREwyTEtDT2RjaHVqQTkwU0ZlMFlTcWNyOXU1QVpjOVF0TnBySjZseHVKMUc4dy1URFBMcnotci1tUjIxYUhIWHVzNVF5LW9QaUNBOGFyZEVxMEhObDk4RzljY2dma2xydnhVa1libXlPZVhr?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Delcath Systems (DCTH) Valuation After New Phase 3 FOCUS Subgroup Data On HEPZATO KIT", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Understanding Momentum Shifts in (DCTH)", "summary": "Delcath Systems Inc. (NASDAQ: DCTH) is showing neutral near-term sentiment with strong mid-term sentiment potentially stalling. The analysis identifies no clear price positioning signal but notes compelling upside potential as no resistance levels remain above the current price. ", "url": "https://news.stocktradersdaily.com/news_release/132/Understanding_Momentum_Shifts_in_DCTH_071126104402_1783824242.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T22:44:00", "published_display": "11 Jul 2026 22:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems (DCTH) Slides 3.77% as Stock Tests Key Support Levels - Flat Correction", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOenpxcFR0VXRGS3pVVkxEVmNJUUJxVGZyZnhIb3NWVEFqeTh6RzRwektrWC1BdXdZQVc5N2RXRmRxVDZEYjBucm4yVWRSUVpOLUV1RmVlSXZwQmVjbHVOM1Q0aGgwakpwMUF3NHB6ZWpUcFFvTjQzcnhoQkJPMmdYYzlLOWVCdGNHcjRmSHV4TnpkT0ZHR2hDTEFLY2dVZG5zRmhOeDliR2hxLXJs?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-11T15:42:03+00:00", "published_display": "11 Jul 2026 15:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervalued", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQNG9xRUQ0elZLbXVRNmVRU3hhQjNSSFRCYWtMTUZ1OEJDWkF3RjQzNFNCVHJlN2RGY3RJLV84dWZNZUhZaDRwWVl2SFhIdWM5OC1oZ2JmcnczS090WXNwendUQWlWYXB5UjA1RF9RdW0telowS1NKdEd2STFRbDNPdEZxbEFPSmowMWZfX1lBN3lfblBpNElZRVpEeVpLSzJBR29FVzdMNXI4Ulh4eC0wZU1tdk5jd204MXpFZm5iaE5zdFcyRy1v?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-10T23:56:15+00:00", "published_display": "10 Jul 2026 23:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Maintains Delcath Systems(DCTH.US) With Buy Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQcGczMVJGUVJad1Rkd2JNLVFmdWtSdmRKZXhWSWVJVzg0LXRFblZISl8yYWV2MFpoYllDeDBDUE9uRElQZEhUbGxPNElMVklMZG9nRERTRFFhbEwwSkllTm9pcmlfdzQtaEZLVS1QRlN6eXMwbGFWbzRLXzg1VW9IYmdVd0JjWmg0S3hoRXN3UU9od3hOczd5XzZJOTJvS1JmUTg2Tg?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-10T11:34:11+00:00", "published_display": "10 Jul 2026 11:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $21", "summary": "CCORF has reiterated its Buy rating for Delcath Systems (DCTH.US), maintaining a target price of $21. This indicates continued confidence from the firm in the company's prospects.", "url": "https://www.moomoo.com/news/post/72780649/ccorf-maintains-delcath-systems-dcthus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-10T12:09:42", "published_display": "10 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Doses First Patient in Mid-Stage Trial of Hepzato", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/delcath-systems-doses-first-patient-124419614.html", "source_name": "MT Newswires", "published_at": "2026-07-09T12:44:19+00:00", "published_display": "09 Jul 2026 12:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath starts Phase 2 HEPZATO trial in metastatic breast cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNTmRLczFUVmJEY09XbkZhSkx3WGY4dzQxYUMzUFprU3JVMFI3eWQ1LVExQTBwYllaX1pQcFJJVG91ZmdveDhEZ0lmeHFwNDg2T1d2R3hwZURqSm1Mcjh1M2dMYkpGUDE4cUlkdHphNk1aR0ZFUzNpa0tqNlk4TmV5VHN6TG9GbHVHa1YwS1FGTUlTdWgxVGtiVWo5NHp0ZmpEdjJSN2htR2Q4SWk4SFd1NUpLVEd6aENGQklyXw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T12:00:00+00:00", "published_display": "09 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems begins Phase 2 breast cancer trial", "summary": "Delcath Systems has dosed the first patient in a Phase 2 trial for its HEPZATO treatment, targeting liver-dominant HER2-negative metastatic breast cancer patients who have failed prior treatments. The trial aims to enroll approximately 90 patients across more than 20 global sites", "url": "https://grafa.com/en/news/united-states/delcath-systems-doses-first-breast-cancer-patient", "source_name": "grafa.com", "published_at": "2026-07-09T12:25:00", "published_display": "09 Jul 2026 12:25", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO\u2122 in Liver-Dominant Metastatic Breast Cancer", "summary": "Delcath Systems announced that the first patient has been dosed in its global Phase 2 clinical trial (DELUMA) evaluating HEPZATO in combination with standard of care for liver-dominant metastatic breast cancer. This randomized, controlled trial will enroll approximately 90 patien", "url": "https://uk.finance.yahoo.com/news/delcath-systems-announces-first-patient-120000662.html", "source_name": "Market source", "published_at": "2026-07-09T12:13:17", "published_display": "09 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath doses first patient in breast cancer trial in Milan", "summary": "Delcath Systems Inc. has dosed the first patient in its Phase 2 clinical trial (DELUMA) in Milan, Italy, evaluating HEPZATO combined with standard of care for liver-dominant metastatic breast cancer. This trial aims to assess the safety and efficacy of HEPZATO in HER2-negative pa", "url": "https://www.investing.com/news/company-news/delcath-doses-first-patient-in-breast-cancer-trial-in-milan-93CH-4783969", "source_name": "Investing.com", "published_at": "2026-07-09T12:13:17", "published_display": "09 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems (DCTH) Gains 2.12% as Stock Approaches Key Resistance Level - GEX Level", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNNkxadUhlNFl0eUdQZDd0TnhjRkZhSm9Dc3hrSlhvaHJjdUZRdTZyQzZsX1FFNjY0N3FJVDRZOHczd01LV1VudTZfRWZUbXZKY0p0NDZ1TnhYZ3l6Y25PcmxMVTZYdVBDWG5qelZYSFNpV0Jxb2JNaHFERF9LT0dqbEVtN0JrZ09uVjV4bXNZbV9RSElWdEdZOHJMSHZaSHNwYy1ZRHB5Zm45SGtkaUZ1ZGN3clF4YzFEN2c?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-07T00:46:34+00:00", "published_display": "07 Jul 2026 00:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Delcath Systems, Inc. \u2013 NASDAQ:DCTH", "summary": "This article provides the \"Price to sales forward\" metric for Delcath Systems, Inc. (NASDAQ: DCTH) on TradingView. It appears to be a financial data snippet rather than an in-depth analysis, focusing solely on this specific financial ratio for the company. The page also includes ", "url": "https://www.tradingview.com/symbols/NASDAQ-DCTH/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T23:10:23", "published_display": "01 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (DCTH) Movement", "summary": "This article provides a real-time signal analysis for Delcath Systems Inc. (DCTH), highlighting strong near and mid-term sentiment and compelling upside potential due to an absence of resistance above the current price. It outlines institutional trading strategies including posit", "url": "https://news.stocktradersdaily.com/news_release/139/Avoiding_Lag:_Real-Time_Signals_in_DCTH_Movement_063026093602_1782869762.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T21:40:52", "published_display": "30 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc.(NasdaqCM:DCTH) added to Russell Small Cap Comp Value Benchmark", "summary": "Delcath Systems, Inc. (NasdaqCM:DCTH) has been added to the Russell Small Cap Comp Value Benchmark. This inclusion is a significant development for the interventional oncology company, whose proprietary products focus on treating primary and metastatic liver cancers. The announce", "url": "https://www.marketscreener.com/news/delcath-systems-inc-nasdaqcm-dcth-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfde8df225", "source_name": "marketscreener.com", "published_at": "2026-06-29T11:10:24", "published_display": "29 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Delcath Systems, Inc. \u2013 SWB:DV3R", "summary": "This article displays the \"Price to book forward\" financial metric for Delcath Systems, Inc. (SWB:DV3R) on the Stuttgart Stock Exchange. It indicates that the market was closed with no trades at the time of the report. The content provides a basic financial overview for this spec", "url": "https://www.tradingview.com/symbols/SWB-DV3R/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T07:09:44", "published_display": "29 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Delcath Systems, Inc. \u2013 NASDAQ:DCTH", "summary": "This article provides financial information for Delcath Systems, Inc. (NASDAQ: DCTH), specifically focusing on its forward price-to-earnings ratio. It displays a \"Period,\" \"Value,\" \"Change,\" and \"Change %\" table, indicating that the data was made by humans. The content is essenti", "url": "https://www.tradingview.com/symbols/NASDAQ-DCTH/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:09:44", "published_display": "29 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc.(NasdaqCM: DCTH) added to Russell 3000 Value Benchmark", "summary": "Delcath Systems, Inc. (NasdaqCM: DCTH), an interventional oncology company specializing in liver cancer treatments, has been added to the Russell 3000 Value Benchmark. This inclusion follows several other recent additions to various Russell indices, including the Russell Microcap", "url": "https://www.marketscreener.com/news/delcath-systems-inc-nasdaqcm-dcth-added-to-russell-3000-value-benchmark-ce7f5fdcd18ef026", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T11:10:24", "published_display": "28 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc.(NasdaqCM: DCTH) added to Russell 2000 Defensive Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPVTZFOTVoYUdRaTlzWnFMd253eDRkYTIxZHVwc1ZsazB4UjIzQTVfLVFVQzREYkRpbk1kNW53SU96RUtjS0FxTEFaaUtPZXNNMVBCZ3N5aEdMWUk2Yk43RDVsTndlWFRVR0huYk04LVRqSzdTc3h4Mmx3cmFuZC1jU3RSV1FEZnJIbGRNeDN5OE5MXzJmRU9ZZWhnUnczaWRfUW1abkczTEhwajVIa0tXZmtFQm85VFVVeldjUDFmNnNQQQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc. Actuals & Estimates (FWB:DV3R)", "summary": "This article provides financial actuals and estimates for Delcath Systems, Inc. (FWB:DV3R), offering insights into its income statement, balance sheet, cash flow, and valuation metrics. It includes analyst forecasts, historical price data, upcoming earnings dates, and details on ", "url": "https://www.tradingview.com/symbols/FWB-DV3R/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T19:40:59", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc. Actuals & Estimates (NASDAQ:DCTH)", "summary": "This article provides an overview of Delcath Systems, Inc. (NASDAQ:DCTH), including its current stock price, historical performance, and analyst forecasts. It details financial actuals and estimates, earnings per share, revenue, net income, and its market capitalization, and also", "url": "https://www.tradingview.com/symbols/NASDAQ-DCTH/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:59", "published_display": "26 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DCTH Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Delcath Systems, Inc. (DCTH) currently trades at $12.32, with analysts providing a 1-year price target ranging from $16.00 to $30.00. The company's stock has seen a 1.90% increase over the past week and a 10.99% rise over the last month, despite a -11.37% decrease over the last y", "url": "https://www.tradingview.com/symbols/NASDAQ-DCTH/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T08:12:24", "published_display": "26 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc. Actuals & Estimates (LS:A2PT5P)", "summary": "This article provides an overview of Delcath Systems, Inc. (A2PT5P) stock, including current price, analyst forecasts, market capitalization, and financial performance. It highlights key financial metrics, past earnings, and upcoming earnings dates, along with offering guidance o", "url": "https://www.tradingview.com/symbols/LS-A2PT5P/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:40:32", "published_display": "26 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotting Winners: Merit Medical Systems (NASDAQ:MMSI) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q1", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPZ3VmWDdGZC04R2RXUUJZTHJqVlJrdnhJYy1LaEJkcHBaWi1sWXdoWS1oLWFlVUQxdFNOQlNDdzhaTHJtMGRkX3pHc1pWbGp0bENwY1h6TlpvWVRWWmJxODh4emhGVDBFajd0VWNmUGNVcnN1SDBXRG9jZFVDa2M4MGFCVFhxbGN0ZXZqSTV2SUE1S3JjMTRnQlBiSnVmR0lv?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Institutional Confidence", "summary": "Delcath Systems Inc (DCTH) has an institutional shareholding score of 3.00, placing it 132nd out of 203 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion decreased by 20.44% quarter-over-quarter to 49.40%, with Bill Nygren | OAKMX being th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T18:39:23", "published_display": "18 Jun 2026 18:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Delcath Systems Inc (DCTH), focusing on its business segments. As of the latest update on April 6, the company's revenue is primarily driven by HEPZATO KIT, accounting for 92.50% of revenue with $78.83 million, while CHEMOSAT contribu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T18:09:53", "published_display": "18 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Delcath Systems Inc (DCTH) currently has a strong financial score of 8.31, placing", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:33", "published_display": "18 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Delcath Systems Inc (DCTH), detailing its current price momentum score, support and resistance levels, and various technical indicator and moving average signals. Currently, the stock's price momentum score is 9.38, suggesting a range", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/technical", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:33", "published_display": "18 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Valuation: PE, PB & Fair Value Analysis", "summary": "Delcath Systems Inc (DCTH) has a current valuation score of 4.97, placing it low within the Healthcare Equipment & Supplies industry. Its P/E ratio stands at 805.54, which is at its recent high and significantly above its recent low. However, relevant data for P/B, P/S, and P/CF ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:33", "published_display": "18 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a detailed look into Delcath Systems Inc (DCTH)'s dividend and stock split history. It states that the company has distributed no dividends in the past five years and has no record of stock splits. The page also displays current market data for DCTH, includin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T10:10:33", "published_display": "18 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Inc (DCTH) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Delcath Systems Inc (DCTH) has an earnings forecast score of 8.57, ranking 26th in the Healthcare Equipment & Supplies industry, with an average price target of $22.00. Based on 6 analysts, the stock has a \"Buy\" rating with a target price of $22.333, representing an upside of 89.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dcth/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:29", "published_display": "17 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 2026 Delcath Systems Inc Earnings Call Transcript", "summary": "This document contains the transcript for Delcath Systems Inc.'s Q1 2026 earnings conference call, which took place on May 7, 2026, at 12:30 PM GMT. The call commenced with an introduction and then transitioned to discussions of the company's first-quarter 2026 earnings. The prov", "url": "https://www.gurufocus.com/stock/STU:DV3R/transcripts/8844756", "source_name": "GuruFocus", "published_at": "2026-06-16T07:40:04", "published_display": "16 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc. Analyst Forecast (DCTH) \u2014 MLQ", "summary": "This article provides an analyst forecast for Delcath Systems, Inc. (DCTH), showing a \"Buy\" consensus from 11 analysts with a 12-month average target price of $23.00. It details forward estimates for revenue, EPS, and net income through 2030, alongside recent grade changes and pr", "url": "https://mlq.ai/stocks/v2/DCTH/stock-forecast/", "source_name": "MLQ.ai", "published_at": "2026-06-08T11:09:53", "published_display": "08 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc. Stock 12\u2011Month Price Target Cut to $20.83, Implies 95% Upside", "summary": "Delcath Systems, Inc.'s average 12-month price target has been lowered to $20.83 from $21.71 by 6 analysts, with individual forecasts ranging from $16 to $30. This new target suggests a potential upside of approximately 95% based on the June 5 closing price. The consensus analyst", "url": "https://www.tradingview.com/news/tradingview:48f8ca0a8615d:0-delcath-systems-inc-stock-12-month-price-target-cut-to-20-83-implies-95-upside/", "source_name": "TradingView", "published_at": "2026-06-06T16:38:54", "published_display": "06 Jun 2026 16:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European cancer guidelines add Delcath liver therapy for eye melanoma", "summary": "Delcath Systems' CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (M-PHP) has been included in the European Society for Medical Oncology (ESMO)\u2013EURACAN Clinical Practice Guidelines for uveal melanoma. This inclusion validates M-PHP as a recommended li", "url": "https://www.stocktitan.net/news/DCTH/delcath-systems-inc-announces-inclusion-of-chemosat-hepatic-delivery-kmiustvc4nvx.html", "source_name": "Stock Titan", "published_at": "2026-06-06T00:38:54", "published_display": "06 Jun 2026 00:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC", "summary": "The article announces that DELCATH SYSTEMS INC (DCTH) has received FDA approval for its product, HEPZATO. This information was disseminated by Quantisnow, a platform providing real-time market data and news to investors. Quantisnow Plus members were alerted of this development sh", "url": "https://www.quantisnow.com/insight/fda-approval-for-hepzato-issued-to-delcath-systems-inc-6578811", "source_name": "Quantisnow", "published_at": "2026-05-29T11:09:13", "published_display": "29 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(DCTH) Movement Within Algorithmic Entry Frameworks", "summary": "Delcath Systems Inc. (NASDAQ: DCTH) is exhibiting weak near-term sentiment that may lead to a resumption of long-term weakness. The article highlights an exceptional 57.7:1 risk-reward short setup and outlines three distinct AI-generated trading strategies with specific entry zon", "url": "https://news.stocktradersdaily.com/news_release/1/DCTH_Movement_Within_Algorithmic_Entry_Frameworks_052826054602_1780004762.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-28T17:46:00", "published_display": "28 May 2026 17:46", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts", "summary": "Delcath Systems, Inc. announced the publication of two investigator-initiated trials-in-progress abstracts for the 2026 ASCO Annual Meeting. These abstracts detail ongoing clinical investigations using Delcath's HEPZATO KIT\u2122 for metastatic melanoma involving the liver. The trials", "url": "https://finance.yahoo.com/sectors/healthcare/articles/delcath-systems-announces-two-asco-200100337.html", "source_name": "Market source", "published_at": "2026-05-27T09:10:06", "published_display": "27 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liver melanoma trials test HEPZATO with systemic treatments at ASCO 2026", "summary": "Delcath Systems announced the publication of two investigator-initiated trials-in-progress abstracts for presentation at the 2026 ASCO Annual Meeting. These abstracts detail ongoing clinical investigations evaluating HEPZATO KIT\u2122 Hepatic Delivery System (HDS) with melphalan in co", "url": "https://www.stocktitan.net/news/DCTH/delcath-systems-announces-two-asco-2026-investigator-initiated-dp5wpwdiapnc.html", "source_name": "Stock Titan", "published_at": "2026-05-27T08:10:45", "published_display": "27 May 2026 08:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems (DCTH) director awarded 22,500 stock options at $11.61", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNWEREWW9nR21FeWppZzFVSmFEbC1UTTRxa2xKRGZQNXNkeGl4d0J0ajdaMDk4elpmMlpRblFLb0VsN28tZTdzRW9uQ1FTSVBwcTRpb1BhRDZ1TllqQ2Q4aTA5V2g1cW1DdkZWNktoMTl1eDhXWjhFT2dySm5hdTZXTTRFeUI2REx3MHk3dUhBaks5Y0dEaGwyZURoc0thcEpoalZiaGI1NVoweWR0SE10dWQ4dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath (DCTH) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/38459c2a-38ca-31ab-a108-c9d47b74b4b4/delcath-%28dcth%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-08T16:25:55+00:00", "published_display": "08 May 2026 16:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems (DCTH) Trailing Profitability Flip Tests Bullish Margin Expansion Narrative", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPTTVmdFA2WW4tUmRJa3VBX3NnVWQybDhzbnJQVzBmVFV0anB2NkQ1WjRGYzhaSmNNdzdwSk0yMFctOG9vYlg5Vnd4ZHh3RjVtM191Zkd3b0VLQ2h4ak5uNHBxSzVfaGVERVdqaWkzeDBTcTJsQ3FHZ3J6UzZ4RDl3RkZaQ1lwaVc2OTNuOGJVREd1MG9nTU1hX2ctejVMQkVKbWEyd25XVllUZ1RtUkFWTjVlckFrZ2JPTzFFNEs2MXViX3l6MVpGamJlbXZTYVlqVGfSAdcBQVVfeXFMUGFselNKQUhYaW4zNE9MX0dqQWhaZHZxWmg1cmNyY1EwOGdoN1ROakRld096NnV2TGNPeVZZclpINjhBbVdUZnBJbmlkcTJSSEhEYnpRbG1oaWh4ZHA5QTk0Z2E3cFpPdlh5Z0FhSVlaeHhZTXFzMEdBeVk3elFRd05mU1c3S0VuNDVYUEpqaUVmLWdESVJrRFV5SW1za0ZXQXVCRTVVc21adXhlMm1JQnRveUhGTTBXUGJ6U29tQUwwV3U0MUNQYVJlVFBmR05WcEtIX1dwNkE?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/7bf08e38-3fd6-340b-89e9-a4a599ba6e25/delcath-systems-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-07T17:42:42+00:00", "published_display": "07 May 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZ0trOWhRTUdSQXN4emRSWU9ucE5zNV9Fc2wwQnBzLTVtOGp5R2NsS0lfV3RkRURBdEpiRW9hVmhsaTNlMGFNcWVRaHhSM18xVTlsRmJVUVJrVExvS3pNM2diODVRRzBJZS04MDhYb0ttVGtkdVdEbkJ0Sjd5TW1PQkY3b1I4b05zNmJBUWJSUzFCSXozTGNNU2cycjU3UQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Delcath Systems (DCTH) Story Is Shifting With Hepzato Milestones And 2026 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNdFhHM2gzQ3FhUjhJNjF4c0xKWWZJS0dCNlJ1UGFjamFIZXQ3Z1l6VmZ2VWM4bUd4djViYlJ3MGI4NnFYOUZUOTQ1TnJUYU0zZHNFMHdVRGxpWThFMFNlLWpVMENnWXQ4MjM3MHVmeEZZOE5uOXN4bkotU3NDOERIVnhLVmdQYUFUQlRaeGZYVVhjcS1jeFZNbXE1OVpOSFd6VFE?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems will discuss Q1 results on a May 7 morning call", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOX1JOdmdKb3FWLU4xRGpLRFJrbmdfM0NiMUFjTERpLWplU3F5QzViM0tJRlNJWXJFd2dXRkdSOXpGUUllek5QNGdyU3lvYmRRNjNlckdLbFB2cFRVT0xDQzh2MWY0TmNyNkRfTUs2b1E2V2JTOVFsNVM4N0xsOWtiY1ZycmFwZ2NBWXBEaGlEM1dteEFRNVVvOWQ5X0xCUGs1QWQ5dG1HOUF4Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T12:42:40+00:00", "published_display": "23 Apr 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q4 Highlights: Merit Medical Systems (NASDAQ:MMSI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQdTQyU1EtSEFYQTdZR0NhU1ZpMVdGNXhiTnlkNm9RWFRka3RfYlZBeklfTFZTRkVaOHBGNi15enNqMGlxVnJad0M5cmp3dUZzYW9Va2tOU19sMnE4V1czcFB4VWRKaVBzYnRtZ0RfVnB5TkloY3U5dW4wQllJMDJaS3BQSVNOMHlVRFQ4aDYtSV9HNTViZXc?oc=5", "source_name": "Market source", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath: Fundamentals Intact, Despite Share Price Weakness (NASDAQ:DCTH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPYWJGWXlzVUNlT1FHSDFZX3Z3OFQ1OHdtOTR0VzBOYXhVS19rVXF1bXk3QjhFazVtMDlJUE1UOS14TGt1SjJNVzhjZHlVZms1aG5SXzZYSTltYXJveVQxNmhqYkZtRjFkVlZPdXNBZjVDNklLS1JpRkFBZXdkbnlEdm16SXB1QkNqT1R4b3JKSmhRRUxJQ0dERjh6LUlRdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade (NASDAQ:DCTH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQZFRsQ2gyeERKNWVTU2M1WW53bDFGTnEwQmwyQmtrMDloWjJhV3UyT19yY1BXQXJhd0JPYXg2TThCRTJqREwyTEtDT2RjaHVqQTkwU0ZlMFlTcWNyOXU1QVpjOVF0TnBySjZseHVKMUc4dy1URFBMcnotci1tUjIxYUhIWHVzNVF5LW9QaUNBOGFyZEVxMEhObDk4RzljY2dma2xydnhVa1libXlPZVhr?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Delcath Systems (DCTH) Valuation After New Phase 3 FOCUS Subgroup Data On HEPZATO KIT", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 64, "sentiment_summary": {"positive": 23, "negative": 4, "neutral": 37, "score": 58, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 16.85, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 11.69, "count": 24}, {"event": "analyst", "label": "Analyst action", "weight": 2.55, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 23, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 13.01, "latest_week": "2026-07-10", "one_week_move": -1.4, "four_week_move": 11.0, "twelve_week_move": 19.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.608374, "market_dynamics_buy_signal": false, "relative_strength": 6.407606, "fair_value_gap": 43.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 46.6698, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.4% over one week, +11.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 15}, {"label": "TradingView", "count": 8}, {"label": "TradingKey", "count": 7}, {"label": "Stock Titan", "count": 5}, {"label": "Stock Traders Daily", "count": 3}, {"label": "GuruFocus", "count": 2}, {"label": "marketscreener.com", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 11}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 24}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.4% over one week, +11.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Understanding Momentum Shifts in (DCTH)"}], "updated_at": "2026-07-16T00:47:32.043720+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}